GENOME THERAPEUTICS CORP

Form 4

March 14, 2003

SEC Form 4

(City)

FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility

Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response..... 0.5

1. Name and Address of Reporting Person*

Labaudiniere, Richard

(Last) (First)
 (Middle)

100 Beaver Street

(Street)

Waltham, MA 02453-8443

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol

Genome Therapeutics Corp. GENE

- 3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)
- 4. Statement for (Month/Day/Year
- 03/12/2003
- 5. If Amendment, Date of Original (Month/Day/Year)
- 6. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

_ Director __10% Owner <u>X</u> Officer (give title below) __ Other (specify below)

Description Development SVP Research &

- 7. Individual or Joint/Group Filing (Check Applicable Line)
- X Form filed by One Reporting Person_ Form filed by More than One Reporting Person

	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1. Title of Security (Instr. 3)	2.Transaction Date (Month/Day/Year)	te Execution Date, if			4. Securities Acquired n(A) or Disposed Of (D) (Instr. 3, 4, and 5)			5. Amount of Securities Beneficially Owned Following	Securities ship Beneficially Form: Owned Direct	7. Nature of Indirect Beneficial Ownership				
			Code	V	Amount	A/D	Price	(Instr. 3 and	Indirect (I) (Instr.	(Instr. 4)				

Table II - Derivative Securities Acquired, Disposed of, or Beneficially (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/ Day/ Year)	3A. Deemed Execution Date, if any (Month/ Day/ Year)	4. Transactio Code (Instr.8)	5. Number of nDerivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)	6. Date Exercisable(DE) and Expiration Date(ED) (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr.5)	9. Nur Der Sec Ber Ow Foll Rep Tra (Ins		

Edgar Filing: GENOME THERAPEUTICS CORP - Form 4

-	-	-	-										
				Code	V	A	D	DE	ED	Title	Amount or Number of Shares		
Stock Options (right to buy)	\$.384	03/12/2003		A		12,360		03/12/2003	03/12/2013	Common Shares	12,360	NA	
Stock Option (right to buy)	\$.384	03/12/2003		A		12,360		03/12/2004	03/12/2013	Common Shares	12,360	NA	25

Explanation of Responses:

 By:
 Date:

 /s/ Richard Labaudiniere
 03/14/03

 ** Signature of Reporting Person
 SEC 1474 (9-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not

required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4(b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).